https://www.selleckchem.com/pr....oducts/pexidartinib-
92 ± 0.15. This value fell steadily with increasing SVFL to a value of 0.38 ± 0.20 when the periphery was not stimulated at all (i.e., the stimulus was a 5-deg. diameter foveal patch). We note considerable individual variation in OKN gain in all conditions. Measuring the extent of visual field loss using an objective measure of OKN gain is feasible. Simulated visual field loss reduces optokinetic nystagmus, but further refinement of this technique would be required to overcome individual differences and to pick up clinicall